By: LPK

In an era where wearable health tech promises real-time insights, accuracy should never be optional. Yet, a recent comparison between the Freestyle Libre 3 and the OneTouch Verio reveals a troubling gap between innovation and reliability.

At the exact moment that the Libre 3 sensor reported a glucose level of 51 mg/dL, a dangerously low reading that could trigger immediate concern, the OneTouch Verio meter showed 124 mg/dL, a completely normal level. The discrepancy is not just significant; it’s alarming, especially considering the Libre system costs over $200 per sensor, compared to roughly $1 per test strip.

So which one does the concerned patient trust?

Continuous glucose monitors (CGMs) like the Libre 3 offer convenience and continuous tracking, but they are not always as “real-time-reliant” as advertised. These devices can lag 10 to 15 minutes behind actual blood glucose levels. Factors such as sensor placement, compression during sleep, dehydration, and temperature fluctuations can further distort readings. Add in the reality that each sensor lasts just 14 days, thus requiring frequent replacement, and users may find themselves paying hundreds monthly for inconsistent data.

When accuracy falters, the consequences extend beyond inconvenience. False readings can lead to unnecessary panic, stress, and even dangerous decision-making. As one user shared, the experience caused “more stress in the last 24 hours than it ever should have.”

Sometimes, the most advanced option isn’t the most dependable. In critical moments, simpler tools, like traditional glucose meters, still prove to be the most trustworthy.